Cemsidomide Shows Immune Reprogramming
C4 Therapeutics reported biomarker evidence that cemsidomide plus dexamethasone activated CD8 T cells and reprogrammed natural-killer cells across 62 heavily pretreated myeloma patients, with stronger effects at 75 and 100 micrograms. In the elranatamab…
